Skip to content
Establishing the Post-IPO IR Program
Establishing the Post-IPO IR Program

Creating awareness for improving performance and a new CFO

The Situation

An Israeli pharmaceutical company trading on TASE engaged LHA upon completion of its U.S. IPO. The company was little known in the U.S. pre-IPO outside of a domestic commercial partnership. The analysts at the company’s syndicate firms a mix of biotechnology and medical devices as the pharmaceutical product was licensed to a firm covered by device analysts. The European Phase 3 study of an inhaled version of its flagship product was viewed as a binary event despite a robust pipeline and other commercial products.

LHA’s Solution

  • Developed and implemented comprehensive IR program with CEO, CFO and CSO involvement.
  • With limited management time in the U.S., focused outreach on arranging multiple conference calls.
  • Targeted primarily biotechnology investors, given the science and clinical/regulatory pathway.
  • Maintained news flow that highlighted advances with other pipeline products.

LHA’s Results

Within the first six months of implementing the program, the company achieved significant results. The post-IPO momentum continued with 65 investor meetings, 10 investor conference calls, two earnings conference calls and presentations at six investor conferences. The company also garnered research coverage from a non-underwriter biotechnology analyst.

LHA Investor Relations is a leading strategic IR consulting agency. We partner with public and private companies to craft and implement effective, custom-designed IR programs that incorporate industry best practices. We are a leader in investor relations for small-cap companies for over 40 years. We go beyond in implementing IR programs that build trust and transparency between our clients and Wall Street. We support capital market objectives by increasing awareness, managing expectations and enhancing reputations.

Back To Top